Insider Transactions in Q1 2025 at Quest Diagnostics Inc (DGX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,823
-16.13%
|
$315,379
$173.74 P/Share
|
|
Mar 04
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,317
+32.0%
|
$919,841
$173.74 P/Share
|
|
Mar 04
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,906
-8.37%
|
$675,738
$173.74 P/Share
|
|
Mar 04
2025
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,549
+15.48%
|
$1,478,977
$173.74 P/Share
|
|
Mar 04
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
592
-1.53%
|
$103,600
$175.79 P/Share
|
|
Mar 04
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
2,280
-9.73%
|
$394,440
$173.74 P/Share
|
|
Mar 04
2025
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
5,674
+19.5%
|
$981,602
$173.74 P/Share
|
|
Mar 04
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
1,879
-12.53%
|
$325,067
$173.74 P/Share
|
|
Mar 04
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
4,434
+22.82%
|
$767,082
$173.74 P/Share
|
|
Mar 04
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
31,656
-15.95%
|
$5,476,488
$173.74 P/Share
|
|
Mar 04
2025
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
61,917
+23.78%
|
$10,711,641
$173.74 P/Share
|
|
Mar 04
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
5,010
-6.39%
|
$866,730
$173.74 P/Share
|
|
Mar 04
2025
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
10,380
+11.69%
|
$1,795,740
$173.74 P/Share
|
|
Mar 04
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
716
-1.04%
|
$125,300
$175.79 P/Share
|
|
Mar 04
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
867
-2.46%
|
$149,991
$173.74 P/Share
|
|
Mar 04
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,711
+4.63%
|
$296,003
$173.74 P/Share
|
|
Mar 04
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,684
-22.56%
|
$1,329,332
$173.74 P/Share
|
|
Mar 04
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
13,884
+28.96%
|
$2,401,932
$173.74 P/Share
|
|
Mar 03
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
322
-0.83%
|
$55,706
$173.74 P/Share
|
|
Mar 03
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
106
-0.59%
|
$18,338
$173.74 P/Share
|
|
Mar 03
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
992
-8.58%
|
$171,616
$173.74 P/Share
|
|
Mar 03
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,662
-1.2%
|
$287,526
$173.74 P/Share
|
|
Mar 03
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
394
-0.57%
|
$68,162
$173.74 P/Share
|
|
Mar 03
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,692
-4.81%
|
$292,716
$173.74 P/Share
|
|
Feb 27
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
824
-1.18%
|
$141,728
$172.61 P/Share
|
|
Feb 27
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
528
-1.33%
|
$90,816
$172.61 P/Share
|
|
Feb 26
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
869
-4.13%
|
$148,599
$171.75 P/Share
|
|
Feb 26
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
455
-0.65%
|
$77,805
$171.75 P/Share
|
|
Feb 26
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
233
-1.98%
|
$39,843
$171.75 P/Share
|
|
Feb 26
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
229
-1.27%
|
$39,159
$171.75 P/Share
|
|
Feb 26
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
286
-0.72%
|
$48,906
$171.75 P/Share
|
|
Feb 26
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,966
-2.1%
|
$507,186
$171.75 P/Share
|
|
Feb 26
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
214
-3.45%
|
$36,594
$171.75 P/Share
|
|
Feb 26
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
88
-0.25%
|
$15,048
$171.75 P/Share
|
|
Feb 20
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
899
-1.26%
|
$152,830
$170.99 P/Share
|
|
Feb 20
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
604
-1.49%
|
$102,680
$170.99 P/Share
|
|
Feb 19
2025
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,031
-4.67%
|
$174,239
$169.71 P/Share
|
|
Feb 19
2025
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
535
-0.74%
|
$90,415
$169.71 P/Share
|
|
Feb 19
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
287
-2.38%
|
$48,503
$169.71 P/Share
|
|
Feb 19
2025
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Open market or private sale
|
Direct |
320
-1.74%
|
$54,080
$169.71 P/Share
|
|
Feb 19
2025
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-0.92%
|
$63,206
$169.71 P/Share
|
|
Feb 19
2025
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,936
-2.04%
|
$496,184
$169.71 P/Share
|
|
Feb 19
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-3.76%
|
$40,898
$169.71 P/Share
|
|
Feb 19
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
99
-0.28%
|
$16,731
$169.71 P/Share
|
|
Feb 12
2025
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,538
+17.05%
|
-
|
|
Feb 12
2025
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
18,149
+11.18%
|
-
|
|
Feb 12
2025
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
454
+1.27%
|
-
|
|
Feb 12
2025
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,815
+21.99%
|
-
|
|
Feb 12
2025
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
3,479
+4.62%
|
-
|
|
Feb 12
2025
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,269
+15.83%
|
-
|